Page 26 - Lupin
Patent infringement: Lupin's arm to pay damages to Bayer
An Australian court has asked Generic Health to pay A$30 million to Bayer Pharmaceuticals
 "Patent infringement: Lupin's arm to pay damages to Bayer")
Lupin expects muted growth in the US despite new launches
About 25 products to be launched next year will only partly compensate price erosion
 "Lupin expects muted growth in the US despite new launches")
Lupin expects muted growth in the US despite new launches
Nilesh Gupta, managing director for Mumbai based pharma major Lupin is trying to reset investors expectation as its mojo in the US market is set to get weaker in the near term.The company that reported Rs 12,958 crore revenue in the nine months of current financial earns about 48% from the US markets. "With one of the strongest pending pipelines in the US at its disposal, the company is well poised to address the pricing issue," said Siddhant Khandekar, analyst with ICICI Securities in its recent report. "We expect US sales to grow at 18% CAGR in FY16-19E to Rs 9642 crore," the report said.Following the $880 million acquisition of Gavis in 2015, the company has stepped-up product launches and ramped-up specialty drugs offering to protect its revenue from the US market.It owns one of the strongest ANDA (Abbreviated New Drug Application) pipeline comprising 344 filed and 137 pending approvals including 44 FTFs (First to File). This acquisition has strengthened its position in ...
Our priority is to acquire speciality drugmakers in the US: Nilesh Gupta
Interview with the managing director of Lupin
Lupin in fast lane with 5 launches in 15 days
New products expected to offset price erosion in the US
Pharma major Lupin launches pain relief drug in US
Shares of Lupin were trading 0.48 per cent higher at Rs 1,454.80 on the BSE
 "Pharma major Lupin launches pain relief drug in US")
Lupin arm to distribute anti-depressant drug in Japan
Kyowa Pharmaceutical has entered into an agreement with Astellas Pharma
Lupin gets USFDA nod for generic cough relief oral solution
The product is generic version of Endo Pharmaceuticals Inc's Hycodan oral solution in same strength
 "Lupin gets USFDA nod for generic cough relief oral solution")
Lupin eyes launch of 25 products in the US in FY18
It now has a portfolio of 128 generic products in the US market
Lupin Q3 profit up 21 pct, beats estimate
Helped by higher sales of its diabetes products in the United States
Lupin gets USFDA nod for generic anti-depressant tablets
Shares of Lupin were trading 1.86 per cent higher at Rs 1,489 apiece on BSE
Lupin gets USFDA nod for hypertension treatment drug in US
Drug major Lupin has received tentative approval from the US health regulator to sell Olmesartan medoximil tablets, used for treating high blood pressure, in the American market. "It has received final approval for Olmesartan medoximil tablets, 5 mg, 20 mg and 40 mg from the US Food and Drug Administration (USFDA)," Lupin Ltd said in a BSE filing today. Olmesartan medoximil tablets, generic version of Daiichi Sankyo's Benicar, are indicated for the treatment of hypertension, along with other antihypertensive agents to lower blood pressure, it added. Quoting IMS MAT September 2016 sales data, Lupin further said that Benicar tablets had annual US sales of USD 1.06 billion. Shares of the company were trading 0.71 per cent up at Rs 1,457 apiece on BSE.
 "Lupin gets USFDA nod for hypertension treatment drug in US")
Lupin to launch sleep disorder drug in US
US business contributes over 40 per cent to the company revenue
 "Lupin to launch sleep disorder drug in US")
Lupin gains on tentative approval for generic Epzicom tablets
The stock was up 3.5% at Rs 1,463 on NSE as compared to 0.02% rise in Nifty50 index
Drug major Lupin gets USFDA nod for generic pain relieving medicine
Lupin's shares were trading at Rs 1,425 apiece on the BSE, up 1.24 per cent from their previous close
Lupin's net profits up 57.8% to Rs 662.2 crore
Lupin's India formulation sales grew by 12.1% to Rs 995.8 cr during Q2 FY2017 as compared to Rs 888.1 cr during Q2 FY2016
Lupin Q2 net up 58% at Rs 662 cr
Consolidated total income jumps 29% to Rs 4,290 cr
US clearance of Goa unit a sales boost for Lupin
With inspection issues out of the way, product nods will gather pace, leading to diversification of revenue stream
Lupin surges on receiving EIR report from USFDA for Goa plant
The stock was up 6% at Rs 1,509 on BSE, as compared to 0.8% rise in the S&P BSE Sensex att 09:26 am.
Lupin, MonoSol Rx sign licensing pact for pediatric products
Lupin Pharmaceutical to develop multiple pediatric products utilising MonoSol Rx's proprietary PharmFilm drug delivery technology
